USPTO Examiner GRABER JAMES J - Art Unit 1631

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18616511Gene Therapy For Neurodegenerative DisordersMarch 2024March 2025Allow1110NoNo
18404087VECTOR-MEDIATED IMMUNE TOLERANCE IN THE EYEJanuary 2024June 2025Abandon1710NoNo
18534884Viral Vectors For Treating Neurogenic Detrusor OveractivityDecember 2023October 2024Abandon1111NoNo
18488346Gene Therapy For Neurodegenerative DisordersOctober 2023April 2025Abandon1810NoNo
18224131CELL-DERIVED PARTICLES PRESENTING HETEROLOGOUS CD24 AND USE THEREOF IN THERAPYJuly 2023October 2024Allow1520YesNo
18351930COMPOSITIONS AND METHODS OF TREATING HUNTINGTON'S DISEASEJuly 2023March 2025Abandon2001NoNo
18142133COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMSMay 2023October 2024Abandon1810YesNo
18309047METHODS FOR EXPANDING A POPULATION OF ALVEOLAR MACROPHAGES IN A LONG TERM CULTUREApril 2023December 2024Abandon2011NoNo
18140326TAIL-CONJUGATED RNASApril 2023May 2024Allow1221YesNo
18167598Compositions and Methods of Treating Ocular DiseasesFebruary 2023January 2025Allow2411YesNo
18152464METHOD FOR ENHANCING PROLIFERATION CAPABILITY OF STEM CELLS USING ETHIONAMIDEJanuary 2023November 2024Allow2331YesNo
18149151Intrathecal Delivery of Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2January 2023March 2025Allow2631YesNo
18068319CELLS EXPRESSING RECOMBINANT GROWTH FACTOR RECEPTORSDecember 2022June 2024Allow1810YesNo
18063589NOVEL ADENO-ASSOCIATED VIRUS CAPSID PROTEINSDecember 2022October 2024Abandon2220NoNo
18057960NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USENovember 2022February 2024Allow1511YesNo
18054500Gene Therapy For Neurodegenerative DisordersNovember 2022January 2024Allow1420YesNo
17982753NUCLEOSIDE MODIFIED MRNA AND USES THEREOFNovember 2022March 2025Allow2822YesNo
18046363Gene Therapy For Neurodegenerative DisordersOctober 2022March 2024Allow1720YesYes
17958904T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFOctober 2022June 2025Abandon3210NoNo
17882127CHIMERIC ANTIGEN RECEPTOR FOR SOLID CANCER AND T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORAugust 2022January 2025Abandon2911NoNo
17882036CHIMERIC ANTIGEN RECEPTOR FOR SOLID CANCER AND T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORAugust 2022January 2025Abandon2911NoNo
17882182CHIMERIC ANTIGEN RECEPTOR FOR SOLID CANCER AND T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORAugust 2022April 2025Abandon3310NoNo
17814287DIMERIZATION SWITCHES AND USES THEREOFJuly 2022August 2024Abandon2511NoNo
17747618COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLSMay 2022June 2024Abandon2511NoNo
17741744ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTSMay 2022February 2023Abandon900NoNo
17709208VISMODEGIB IN COMBINATION WITH A REPLICATION-DEFICIENT TYPE 5 ADENOVIRUS FOR EXPRESSION OF INTERFERON GAMMA FOR THE TREATMENT OF SKIN CANCERMarch 2022March 2025Abandon3510NoNo
17681167UNIVERSAL CAR-T CELL AND PREPARATION METHOD AND USE THEREOFFebruary 2022March 2025Allow3611YesNo
17623978Use of LRP2 Agonists for Generating Myeloid-Derived Suppressor CellsDecember 2021July 2024Allow3011YesNo
17540289METHOD FOR PREVENTING OR TREATING METABOLIC DISORDERDecember 2021July 2023Allow1901YesNo
17523627COMPOSITIONS AND METHODS FOR SELECTIVE GENE REGULATIONNovember 2021June 2025Allow4311YesNo
17516149TUMOR CELL VACCINESNovember 2021February 2024Abandon2711NoNo
17606890OPTIMIZED SUMF1 GENES AND EXPRESSION CASSETTES AND THEIR USEOctober 2021June 2025Allow4311NoNo
17604556GENE THERAPIES FOR STARGARDT DISEASE (ABCA4)October 2021July 2025Allow4411YesNo
17503132COMPLEMENTARY RNA LINKED BISPECIFIC T-CELL ENGAGING ANTIBODIESOctober 2021March 2024Allow2911YesNo
17447231VECTORIZED ANTIBODIES AND USES THEREOFSeptember 2021April 2024Abandon3111NoNo
17342013SYNP162, A PROMOTER FOR THE EXPRESSION OF GENESJune 2021November 2022Allow1700YesNo
17327719CELL-DERIVED PARTICLES PRESENTING HETEROLOGOUS CD24 AND USE THEREOF IN THERAPYMay 2021August 2023Abandon2741NoNo
17325417Methods and Gene Therapy Constructs for Treating GM2 GangliosidosesMay 2021December 2022Allow1900YesNo
17288075PHARMACEUTICAL COMPOSITION COMPRISING ISOLATED MITOCHONDRIA FOR PREVENTING OR TREATING TENDINOPATHYApril 2021June 2025Allow5020NoNo
17223875SYNP159, A PROMOTER FOR THE EXPRESSION OF GENESApril 2021October 2022Allow1900YesNo
17222812GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOFApril 2021September 2022Allow1721YesNo
17209035Method for Producing Culture Containing Megakaryocytes, and Method for Producing Platelets Using SameMarch 2021January 2024Allow3411YesNo
17274062CHIMERIC ANTIGEN RECEPTOR FOR SOLID CANCER AND T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORMarch 2021January 2025Abandon4701NoNo
17186039CELL-DERIVED PARTICLES PRESENTING HETEROLOGOUS CD24 AND USE THEREOF IN THERAPYFebruary 2021December 2023Abandon3441YesYes
17183593METHODS OF MODULATING M2 MACROPHAGE POLARIZATION AND USE OF SAME IN THERAPYFebruary 2021June 2024Abandon4001NoNo
17268328CAR T-CELLS COMPRISING AN ANTI CD33, AN ANTI CLL1 AND AT LEAST ONE FURTHER CAR ANTI CD123 AND/OR FTL3February 2021November 2024Abandon4511NoNo
17141142BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLSJanuary 2021May 2024Abandon4021NoNo
17256141Composition and Methods for Producing Insulin Producing Islet CellsDecember 2020January 2025Allow4921YesNo
17133187MODIFIED NATURAL KILLER CELLS AND NATURAL KILLER CELL LINES HAVING INCREASED CYTOTOXICITYDecember 2020October 2024Abandon4521YesNo
17107461ADENO-ASSOCIATED VIRUS VARIANTS AND METHODS OF USE THEREOFNovember 2020November 2023Abandon3610NoNo
17055525MANIPULATING ARID5B EXPRESSION IN IMMUNE CELLS TO PROMOTE METABOLISM, SURVIVAL, AND FUNCTIONNovember 2020June 2024Allow4311YesNo
17096502MODULATION OF LIVER GENESNovember 2020August 2023Abandon3301NoNo
17084963NOVEL THERAPEUTICAL TOOLS AND METHODS FOR TREATING BLINDNESS BY TARGETING PHOTORECEPTORSOctober 2020November 2023Allow3611YesNo
16771781METHOD FOR PRODUCING ACTIVE GCMAFOctober 2020March 2025Allow5730YesNo
17050694ANTI-BCMA CAR-T-CELLS FOR PLASMA CELL DEPLETIONOctober 2020January 2024Abandon3901NoNo
17047761Cell-Containing Hydrogel Body and Method for Producing SameOctober 2020March 2025Allow5321YesNo
17047515Modification of Immune Cells to Increase ActivityOctober 2020July 2024Abandon4511NoNo
17041435RECOMBINANT VIRAL VECTOR AND USES THEREOFSeptember 2020June 2025Abandon5631YesNo
17024340COMPOSITIONS AND METHODS COMPRISING THE USE OF A BACILLUS AGARADHAERENS INULOSUCRASE (INUO)September 2020August 2023Allow3511YesNo
16976408METHODS AND COMPOSITIONS FOR ANTIBODY-EVADING VIRUS VECTORSAugust 2020December 2024Allow5221NoNo
16975973IMMUNE CELL ACTIVATIONAugust 2020April 2024Abandon4401NoNo
16966264DNA-CHIMERIC ANTIGEN RECEPTOR T CELLS FOR IMMUNOTHERAPYJuly 2020January 2025Allow5431YesNo
16935250CELL CULTURING DEVICE AND METHODJuly 2020April 2024Abandon4501NoNo
16962501METHOD OF ISOLATION OF STEM CELLS FROM HYPERTHERMIA CONDITIONED TISSUES AND USING THE SAMEJuly 2020January 2024Abandon4201NoNo
16889914TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPYJune 2020October 2022Abandon2921YesNo
16766280METHODS OF PRODUCING POPULATIONS OF MESENCHYMAL STEM CELLS FROM PERIPHERAL BLOOD AND USES THEREOFMay 2020February 2025Abandon5731NoNo
16627875Method For Enhancing Proliferation Capability Of Stem Cells Using EthionamideDecember 2019July 2023Abandon4221YesNo
16620738RECOMBINANT HERPES SIMPLEX VIRUS, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOFDecember 2019December 2022Abandon3701NoNo
16617753VISIBLE LIGHT POLYMERIZATION OF POLYETHYLENE GLYCOL (PEG) HYDROGELSNovember 2019December 2023Abandon4841YesNo
16611041COMPOSITIONS AND METHODS OF TREATING HUNTINGTON'S DISEASENovember 2019April 2023Allow4111YesNo
16657944COMPOSITIONS AND METHODS FOR TRANSGENE EXPRESSION FROM AN ALBUMIN LOCUSOctober 2019November 2023Abandon4911NoNo
16606567IDENTIFICATION OF T-CELL TRAFFICKING GENES AND USES THEREOF FOR INCREASING INFILTRATION OF T-CELLS INTO SOLID TUMORSOctober 2019October 2024Allow6041YesNo
16604618ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF STARGARDT DISEASEOctober 2019July 2024Allow5821YesYes
16495184TRANSGENIC c-MPL PROVIDES LIGAND-DEPENDENT CO-STIMULATION AND CYTOKINE SIGNALS TO TCR-ENGINEERED T CELLSSeptember 2019February 2024Abandon5321NoNo
16491869ENGINEERED CELLS AND AGENT COMPOSITIONS FOR THERAPEUTIC AGENT DELIVERY AND TREATMENTS USING SAMESeptember 2019May 2023Abandon4401NoNo
16487323T CELLS EXPRESSING CHEMOKINE RECEPTORS FOR TREATING CANCERAugust 2019June 2023Abandon4621NoNo
16486681ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSIDS AND METHODS OF USE THEREOFAugust 2019August 2023Abandon4811YesNo
16542721Protection of Beta Cells from Immune AttackAugust 2019March 2023Allow4322YesNo
16476595T CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTORJuly 2019July 2024Allow6051YesNo
16466336METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF TUMORSJune 2019September 2024Allow6022YesYes
16464730METHODS AND COMPOSITIONS FOR CANCER THERAPYMay 2019November 2023Abandon5320NoNo
16419874COMPOSITION FOR ENDOGENOUS PRODUCTION OF CHECKPOINT PROTEIN PRECURSORSMay 2019October 2024Abandon6041YesNo
16461837INTRATHECAL DELIVERY OF RECOMBINANT ADENO-ASSOCIATED VIRUS ENCODING METHYL-CPG BINDING PROTEIN 2May 2019September 2022Allow4000YesNo
16347461AAV DELIVERY OF SHRNA FOR TREATMENT OF PANCREATIC CANCERMay 2019May 2023Allow4840YesNo
16346565REGULATABLE CELL LINES AND METHODS OF USE THEREOFMay 2019December 2023Abandon5521NoYes
16346163COMPOSITIONS AND METHODS FOR IMPEDING TRANSCRIPTION OF EXPANDED MICROSATELLITE REPEATSApril 2019August 2024Allow6041YesNo
16395999COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMSApril 2019January 2023Allow4521NoNo
16343869Methods and Systems for T Cell ExpansionApril 2019August 2023Abandon5240YesNo
16386907HUMAN NEURAL PRECURSOR CELLS WITH INDUCIBLE STIM1 KNOCKDOWNApril 2019October 2023Allow5431YesNo
16337428METHOD FOR THE TREATMENT OR PREVENTION OF PAIN OR EXCESSIVE NEURONAL ACTIVITY OR EPILEPSYMarch 2019May 2023Abandon5021NoNo
16319877NOVEL ADENO-ASSOCIATED VIRUS CAPSID PROTEINSJanuary 2019September 2022Allow4311YesNo
16318070VECTOR-MEDIATED IMMUNE TOLERANCE IN THE EYEJanuary 2019August 2023Allow5531YesNo
16312491ENHANCED HETATOPOIETIC STEM CELL TRANSPLANTATIONDecember 2018May 2023Abandon5231NoNo
16099831METHOD OF DETERMINING AUTOPHAGOSOME FLUX AND USES THEREOFNovember 2018March 2025Allow6031YesYes
16099329T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFBRIINovember 2018October 2022Abandon4721NoNo
16145859Non-Human Animals Comprising A Humanized TTR Locus And Methods Of UseSeptember 2018April 2023Abandon5531NoNo
16087471PREPARATION OF PLATELET PELLET LYSATE AND ITS USE FOR TREATING NEUROLOGICAL DISORDERSSeptember 2018December 2024Allow6061YesNo
16134983FATS AS A TARGET FOR TREATING TUMORS AND USES THEREOFSeptember 2018June 2023Abandon5731NoNo
16082035CELLS EXPRESSING MULTIPLE CHIMERIC ANTIGEN RECEPTOR (CAR) MOLECULES AND USES THEREFORESeptember 2018July 2023Abandon5822NoNo
16080369REGULARLY ARRANGED SPHEROIDS HAVING EQUAL SIZES AND USE THEREOFAugust 2018May 2025Abandon6070NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GRABER, JAMES J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
0
(0.0%)
Examiner Reversed
1
(100.0%)
Reversal Percentile
91.2%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
10
Allowed After Appeal Filing
2
(20.0%)
Not Allowed After Appeal Filing
8
(80.0%)
Filing Benefit Percentile
21.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GRABER, JAMES J - Prosecution Strategy Guide

Executive Summary

Examiner GRABER, JAMES J works in Art Unit 1631 and has examined 121 patent applications in our dataset. With an allowance rate of 44.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.

Allowance Patterns

Examiner GRABER, JAMES J's allowance rate of 44.6% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by GRABER, JAMES J receive 2.28 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GRABER, JAMES J is 45 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +64.8% benefit to allowance rate for applications examined by GRABER, JAMES J. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.8% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 15.0% of cases where such amendments are filed. This entry rate is in the 10% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 83.3% of appeals filed. This is in the 73% percentile among all examiners. Of these withdrawals, 80.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 70.8% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.7% of allowed cases (in the 75% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.